Form 4: ARS Pharmaceuticals' Chief Medical Officer Sarina Tanimoto Sells Shares Under 10b5-1 Plan

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Sarina Tanimoto, the Chief Medical Officer of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on May 7, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• The shares were sold in two transactions, each involving 50,000 shares, with weighted average prices of $9.3427 and $9.3446 respectively.
• Following the transactions, Tanimoto directly owns 3,407,847 shares of common stock.
• Tanimoto also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Sarina Tanimoto Charitable Remainder UniTrust, as well as shares held by her spouse.
• The total number of indirectly owned shares is 7,761,659.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the pre-planned nature of the transaction.

Key Dates